OncLive TV

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Ravi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Lewis Au, MBBS, BMedSci, FRACP, discusses the results of a subgroup analysis evaluating antibody responses to COVID-19 in patients with cancer.

Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

Michael R. Charlton, MD, MBBS, discusses the effects of the COVID-19 pandemic on hepatocellular carcinoma.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.

William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies.

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Jane L. Meisel, MD, discusses the potential utility of CDK4/6 inhibitors in HER2-positive metastatic breast cancer.

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Saad Z. Usmani, MD, FACP, discusses optimizing treatment selection in relapsed/refractory multiple myeloma.

Lewis Au, MBBS, BMedSci, FRACP, discusses antibody responses to COVID-19 observed in patients with cancer.

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.